Net Health从 WebPT收购了 Keet Health全球临床试验公司达成最终协议，将收购 Catalyst Clinical Research-动脉网

Net Health Acquired Keet Health from WebPT | Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research

Healthcare IT Today 等信源发布 2026-02-02 22:07



可切换为仅中文







Check out today’s featured companies who have recently completed an M&A deal, and be sure to check out the full list of past

查看今天那些最近刚完成并购交易的特色公司，并务必查看过去的完整列表

healthcare IT M&A

医疗IT并购

。

Net Health Advances Rehab Therapy Care with Acquisition of Keet Health from WebPT

Net Health通过从WebPT收购Keet Health，推动康复治疗护理的发展。

Acquisition Expands Market Access to Industry-Leading Outcomes and RTM Capabilities, Advancing Hybrid Care Across the Rehab Therapy Continuum

收购扩大了市场准入，获得了行业领先的结果和RTM能力，推动了康复治疗连续体中的混合护理。

Net Health

网络健康状况

, a trusted provider of specialized software for rehab therapy and post-acute care, today announced the acquisition of Keet Health, a WebPT company, as part of a strategic collaboration with WebPT focused on advancing outcomes measurement and remote therapeutic monitoring (RTM) for rehabilitation therapy providers..

，一家值得信赖的康复治疗和急性后期护理专业软件提供商，今天宣布收购WebPT旗下的Keet Health公司，这是与WebPT战略协作的一部分，专注于推进康复治疗提供商的结果测量和远程治疗监测（RTM）。

Net Health’s acquisition of Keet Health expands access to Net Health’s Limber platform — the industry’s leading solution for outcomes measurement, RTM, and digital home exercise programs. In connection with the transaction, Limber will become the preferred outcomes and RTM solution for WebPT and Clinicient customers, with an integrated experience targeted for early 2026..

Net Health收购Keet Health扩大了Net Health的Limber平台的访问范围——这是行业领先的结局测量、RTM和数字家庭锻炼计划解决方案。通过此次交易，Limber将成为WebPT和Clinicient客户的首选结局和RTM解决方案，并计划在2026年初提供集成体验。

“Better outcomes are driven by better insights and stronger connections across the continuum of care,” said Ron Books, CEO at Net Health. “Through our collaboration with WebPT, we’re advancing outcomes measurement and remote monitoring in ways that help rehab providers extend care beyond the clinic, reduce fragmentation, and keep the focus where it belongs — on patients.”.

“更好的结果是由更好的洞察力和在整个护理过程中更强的联系所推动的，”Net Health首席执行官Ron Books表示。“通过我们与WebPT的合作，我们正在推进结果测量和远程监控的方式，帮助康复服务提供者将护理扩展到诊所之外，减少碎片化，并将焦点放在应有的地方——患者身上。”

Limber

柔韧的

, which Net Health acquired in 2025, is a leading platform for outcomes measurement, RTM enablement, and home exercise delivery for rehab therapy providers. The solution delivers outcomes-informed insights that help clinicians monitor progress, personalize care, and support patients beyond traditional clinic visits.

，Net Health于2025年收购，是康复治疗提供商领先的成果测量、RTM支持和家庭锻炼交付平台。该解决方案提供基于结果的洞察，帮助临床医生监测进展、个性化护理，并在传统诊所访问之外支持患者。

Net Health continues to invest in Limber’s analytics and integration capabilities as part of its broader platform strategy to support value-based care. Net Health and WebPT also plan to invest in deeper integration between Limber and the WebPT and Clinicient platforms. The integration is intended to streamline workflows, strengthen data continuity, and support more connected digital health experiences as patients transition between care settings..

Net Health继续投资于Limber的分析和集成能力，作为其更广泛的平台战略的一部分，以支持基于价值的护理。Net Health和WebPT还计划加强Limber与WebPT和Clinicient平台之间的深度集成。该集成旨在简化工作流程，增强数据连续性，并在患者在不同护理环境之间转换时提供更加连贯的数字健康体验。

“Our work with Net Health gives our members access to a powerful digital health solution while preserving the flexibility and choice they expect,” said Andrea Facini, CEO at WebPT…

“我们与Net Health的合作为我们的成员提供了一个强大的数字健康解决方案，同时保留了他们所期望的灵活性和选择权，”WebPT首席执行官安德烈亚·法奇尼表示。

Full release here

完整发布在这里

, originally announced January 15th, 2026.

，最初宣布于2026年1月15日。

Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research

全球临床试验公司达成最终协议收购催化剂临床研究公司

Combination to Add Key Functional Service Provider Capabilities, Deliver Immediate Uplift in Oncology, Strengthen Global Site Reach, and Accelerate Technology Integration – Enhancing Speed, Transparency, and Value for Customers

结合增加关键功能服务提供商的能力，立即提升肿瘤学领域实力，加强全球站点覆盖，并加速技术整合——为客户提供更快的速度、更高的透明度和更大的价值。

Worldwide Clinical Trials

全球临床试验

, a global contract research organization (CRO), has entered into a definitive agreement to acquire

，一家全球合同研究组织（CRO），已达成最终协议收购

Catalyst Clinical Research, LLC

催化剂临床研究有限公司

, a specialized oncology CRO, known for its expertise in early phase oncology trials and a strong biometrics and Functional Service Provider (FSP) model. Following the close of the transaction, Nick Dyer, Chairman of the Board at Catalyst, will join Worldwide’s Board of Directors, and Nik Morton, President and CEO at Catalyst, will join Worldwide’s executive leadership team..

，一家专注于肿瘤学的合同研究组织（CRO），以其在早期肿瘤学试验方面的专业知识以及强大的生物统计学和功能性服务提供商（FSP）模式而闻名。交易完成后，Catalyst董事会主席尼克·戴尔将加入Worldwide的董事会，Catalyst总裁兼首席执行官尼克·莫顿将加入Worldwide的执行领导团队。

This strategic combination creates immediate value for customers by establishing Worldwide as a leading oncology-focused CRO, while maintaining depth across multiple therapeutic areas and strengthening its footprint and scale to deliver larger global trials. The integration of Catalyst’s two established solutions – Catalyst Oncology and Catalyst Flex – will strengthen Worldwide’s portfolio, offering customers proven expertise and new services for full-service, FSP resourcing, and hybrid solutions.

这一战略性组合通过将Worldwide确立为领先的专注于肿瘤学的CRO，为客户创造即时价值，同时保持在多个治疗领域的深度，并增强其在全球范围内开展更大规模试验的影响力和规模。Catalyst的两个成熟解决方案——Catalyst Oncology和Catalyst Flex——的整合将加强Worldwide的产品组合，为客户提供经过验证的专业知识以及全服务、FSP资源和混合解决方案的新服务。

Additionally, the integration of complementary technology platforms and best-in-class operational practices will enable enhanced data visibility and improved efficiency throughout the development lifecycle – helping customers bring life-changing therapies to patients more quickly..

此外，整合互补的技术平台和业内最佳的操作实践将提高整个开发周期中的数据可见性和效率，帮助客户更快地将改变生命的疗法带给患者。

“Bringing Worldwide and Catalyst together elevates our capabilities in oncology and provides a new solution for our collective customers,” said

“将Worldwide和Catalyst结合在一起，提升了我们在肿瘤学领域的能力，并为我们的共同客户提供了新的解决方案，”

Alistair Macdonald

艾利斯泰尔·麦克唐纳

, Chief Executive Officer at Worldwide. “We are excited to add Catalyst’s deep operational expertise and oncology credibility to our own well-known CNS specialist CRO capabilities to create a differentiated biotech-oriented oncology solution. Our combined customers seek focused senior executive connection and attention, predictability, speed, flexibility, and scientific rigor.

世界首席执行官表示：“我们很高兴将Catalyst深厚的运营专业知识和肿瘤学信誉与我们自身知名的中枢神经系统专科CRO能力相结合，以打造一个差异化且面向生物技术的肿瘤学解决方案。我们的共同客户期望专注的高层管理联系和关注、可预测性、速度、灵活性以及科学严谨性。

They will benefit from the addition of a scalable FSP model with integrated onshore/offshore service lines, while we leverage advanced business management tools and AI to drive operational excellence. Beyond the science, this is about people – bringing together talented teams, expanding opportunities, and working together to deliver more agile trials for our customers.”.

他们将受益于增加了一个具有集成在岸/离岸服务线的可扩展FSP模型，同时我们利用先进的业务管理工具和人工智能来推动运营卓越。除了科学之外，这关乎人员——汇集有才华的团队，扩大机会，并共同努力为我们的客户交付更灵活的试验。”

Matt Jennings

马特·詹宁斯

, Executive Chairman at Worldwide and Senior Operating Partner at

全球执行主席兼高级运营合伙人

Kohlberg

科尔伯格

, the majority owner of the Company, commented, “Integrating Catalyst will accelerate Worldwide’s growth in oncology and expand both its customer base and global reach simultaneously. Their specialized expertise, innovative platforms, and strong relationships with emerging biotech sponsors align perfectly with our vision for building a differentiated, technology-enabled CRO.

“整合Catalyst将加速Worldwide在肿瘤学领域的增长，同时扩大其客户群和全球影响力。他们在新兴生物技术赞助商方面的专业经验、创新平台和强大关系，完全符合我们构建差异化、技术驱动型CRO的愿景。”公司大股东评论道。

This is a strategic step toward creating a more agile and competitive organization that can meet the evolving needs of clinical research globally.”.

这是朝着创建一个更灵活、更具竞争力的组织迈出的战略性一步，该组织能够满足全球临床研究不断变化的需求。

“This marks an exciting new chapter for both Catalyst and Worldwide. By joining forces, Catalyst brings our specialized early phase oncology expertise together with Worldwide’s strength in late phase development, expanding our global footprint and delivering differentiated oncology solutions globally,” said .

“这标志着Catalyst和Worldwide一个令人兴奋的新篇章。通过联手，Catalyst将我们早期肿瘤学的专业知识与Worldwide在后期开发中的优势结合在一起，扩大我们的全球足迹，并在全球范围内提供差异化的肿瘤解决方案，”表示。

Nik Morton

尼克·莫顿

, President and Chief Executive Officer at Catalyst…

，催化剂公司的总裁兼首席执行官…

Full release here

完整发布在这里

, originally announced January 20th, 2026.

，最初宣布于2026年1月20日。